Safety concerns include thrombocytopenia and glomerulonephritis, which were monitorable and manageable following implementation of more frequent platelet (weekly) and renal (every 2–3 weeks) monitoring in the NEURO‐TTR study (Benson et al., 2018). The gene discussed is TTR; the disease is Thrombocytopenia.